PMID- 12467217
OWN - NLM
STAT- MEDLINE
DCOM- 20030116
LR  - 20210109
IS  - 1535-7163 (Print)
IS  - 1535-7163 (Linking)
VI  - 1
IP  - 3
DP  - 2002 Jan
TI  - Cellular and molecular pharmacology of oxaliplatin.
PG  - 227-35
AB  - Oxaliplatin, a diaminocyclohexane-containing platinum, has a spectrum of activity 
      and mechanisms of action and resistance that appear to be different from those of 
      other platinum-containing compounds, notably cisplatin. The first part of this 
      review describes the differences between oxaliplatin and cisplatin in terms of 
      their spectrum of activity and adduct formation and then goes on to discuss 
      molecular and cellular experimental data that potentially explain them. 
      Particular emphasis is placed on the differential role of DNA repair mechanisms. 
      In addition, the anticancer effects of oxaliplatin are optimized when it is 
      administered in combination with other anticancer agents, such as 5-fluorouracil, 
      gemcitabine, cisplatin, or carboplatin; topoisomerase I inhibitors; and taxanes. 
      In vitro and preclinical combination data that could optimize oxaliplatin-based 
      chemotherapy are also reviewed.
FAU - Raymond, Eric
AU  - Raymond E
AD  - Department of Medicine, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 
      Villejuif, France. raymond@igr.fr
FAU - Faivre, Sandrine
AU  - Faivre S
FAU - Chaney, Stephen
AU  - Chaney S
FAU - Woynarowski, Jan
AU  - Woynarowski J
FAU - Cvitkovic, Esteban
AU  - Cvitkovic E
LA  - eng
GR  - CA78706/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Mol Cancer Ther
JT  - Molecular cancer therapeutics
JID - 101132535
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA Adducts)
RN  - 0 (Organoplatinum Compounds)
RN  - 04ZR38536J (Oxaliplatin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Biotransformation
MH  - DNA Adducts
MH  - DNA Repair
MH  - Drug Resistance, Neoplasm
MH  - Drug Synergism
MH  - Humans
MH  - Organoplatinum Compounds/*pharmacology
MH  - Oxaliplatin
RF  - 100
EDAT- 2002/12/07 04:00
MHDA- 2003/01/17 04:00
CRDT- 2002/12/07 04:00
PHST- 2002/12/07 04:00 [pubmed]
PHST- 2003/01/17 04:00 [medline]
PHST- 2002/12/07 04:00 [entrez]
PST - ppublish
SO  - Mol Cancer Ther. 2002 Jan;1(3):227-35.